Pacira BioSciences, Inc.
PCRXHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jun 3, 2026
Scan Results
Daily timeframePacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. At a $875.5M market cap, Pacira BioSciences, Inc. ranks as a small-cap company within healthcare. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve.
Market Cap
$875.5M
Beta
0.32
P/E (TTM)
171.15
P/E (Fwd)
6.11
EPS (TTM)
$0.13
EPS (Fwd)
$3.64
ROE
0.7%
ROA
1.4%
Cash
$202.2M
Total Debt
$411.2M
Free CF
$98.6M
52W Change
-17.5%
Annual Financials
Cash vs Debt
Pacira BioSciences, Inc. carries $411.2M in total debt against $202.2M in cash reserves — debt is roughly 2.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $98.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 0.7%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.4% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $666.8M (2022) to $726.4M (2025).
The relatively low beta of 0.32 suggests PCRX is a less volatile holding compared to the broader index. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Pacira BioSciences, Inc. and its sector.